Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma

Enrico Derenzini, Claudio Agostinelli, Enrica Imbrogno, Ilaria Iacobucci, Beatrice Casadei, Elisa Brighenti, Simona Righi, Fabio Fuligni, Andrea Ghelli Luserna Di Rorà, Anna Ferrari, Giovanni Martinelli, Stefano Pileri, Pier Luigi Zinzani

Research output: Contribution to journalArticlepeer-review


The recent finding that MYC-driven cancers are sensitive to inhibition of the DNA damage response (DDR) pathway, prompted us to investigate the role of DDR pathway as therapeutic target in diffuse large B-cell lymphoma (DLBCL), which frequently overexpresses the MYC oncogene. In a preliminary immunohistochemical study conducted on 99 consecutive DLBCL patients, we found that about half of DLBCLs showed constitutive expression of the phosphorylated forms of checkpoint kinases (CHK) and CDC25c, markers of DDR activation, and of phosphorylated histone H2AX (?H2AX), marker of DNA damage and genomic instability. Constitutive ?H2AX expression correlated with c-MYC levels and DDR activation, and defined a subset of tumors characterised by poor outcome. Next, we used the CHK inhibitor PF-0477736 as a tool to investigate whether the inhibition of the DDR pathway might represent a novel therapeutic approach in DLBCL. Submicromolar concentrations of PF-0477736 hindered proliferation in DLBCL cell lines with activated DDR pathway. These results were fully recapitulated with a different CHK inhibitor (AZD-7762). Inhibition of checkpoint kinases induced rapid DNA damage accumulation and apoptosis in DLBCL cell lines and primary cells. These data suggest that pharmacologic inhibition of DDR through targeting of CHK kinases may represent a novel therapeutic strategy in DLBCL.

Original languageEnglish
Pages (from-to)6553-6569
Number of pages17
Issue number9
Publication statusPublished - 2015


  • CHK1
  • CHK2
  • Diffuse large B-cell Lymphoma
  • Gamma-H2AX
  • Genomic instability
  • MYC

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

Cite this